CCMI
Based on 2 publication(s) in Google Scholar
CCMI (AVL-3288) is a potent and selective α7 nAChR-positive allosteric modulator, does not bind to or activate α7 nAChRs via the orthosteric site, and causes significant positive modulation of agonist-induced currents at α7 nAChRs. CCMI has potential in CNS diseases with cognitive dysfunction.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 917837-54-8
- Formula: C19H15Cl2N3O2
- Molecular Weight:388.25
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
Clinical Compound Library
HY-L026
-
Covalent Screening Library
HY-L036
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Targeted Diversity Library
HY-L099
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Activators Library
HY-L159
-
Ion Channel Compound Library
HY-L166
-
Allosteric Modulators (AMs) Compound Library
HY-L170
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) CCMI
More
Biological Activity
α7 nAChR[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Oocyte | EC50 |
0.5 μM
Compound: 6
|
Activation of human alpha-7 nAChR expressed in Xenopus oocytes assessed as modulation of nicotine-induced current by two-electrode voltage-clamp method
Activation of human alpha-7 nAChR expressed in Xenopus oocytes assessed as modulation of nicotine-induced current by two-electrode voltage-clamp method
|
[PMID: 17470817] |
| Oocyte | EC50 |
0.6 μM
Compound: 6
|
Activation of human alpha-7 nAChR expressed in Xenopus oocytes assessed as modulation of choline-induced current by two-electrode voltage-clamp method
Activation of human alpha-7 nAChR expressed in Xenopus oocytes assessed as modulation of choline-induced current by two-electrode voltage-clamp method
|
[PMID: 17470817] |
| Oocyte | EC50 |
0.7 μM
Compound: 6
|
Activation of human alpha-7 nAChR expressed in Xenopus oocytes assessed as modulation of acetyl choline -induced current by two-electrode voltage-clamp method
Activation of human alpha-7 nAChR expressed in Xenopus oocytes assessed as modulation of acetyl choline -induced current by two-electrode voltage-clamp method
|
[PMID: 17470817] |
| Oocyte | EC50 |
6.3 μM
Compound: 6
|
Activation of human GABAA alpha-2-beta-3-gamma-2L receptor expressed in Xenopus oocytes assessed as modulation of GABA-induced current by two-electrode voltage-clamp method
Activation of human GABAA alpha-2-beta-3-gamma-2L receptor expressed in Xenopus oocytes assessed as modulation of GABA-induced current by two-electrode voltage-clamp method
|
[PMID: 17470817] |
CCMI (Compound 6) is a potent and selective α7 nAChR-positive allosteric modulator, does not bind to or activate α7 nAChRs via the orthosteric site, and causes significant positive modulation of agonist-induced currents at α7 nAChRs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 917837-54-8
-
Appearance Solid
-
Molecular Weight 388.25
-
Formula C19H15Cl2N3O2
-
Color Light yellow to yellow
-
SMILES
O=C(NC1=CC=C(Cl)C=C1)/C(C2=CC(C)=NO2)=C/NC3=CC=C(Cl)C=C3
-
Synonyms
AVL-3288; UCI-4083
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Pharmacol Biochem Behav
Chronic administration of caffeine, modafinil, AVL-3288 and CX516 induces time-dependent complex effects on cognition and mood in an animal model of sleep deprivation. [Abstract]2024 May 30:173793. PMID: 38823543 -
Solvent & Solubility
DMSO : 100 mg/mL (257.57 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.36 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5757 mL | 12.8783 mL | 25.7566 mL | 64.3915 mL |
| 5 mM | 0.5151 mL | 2.5757 mL | 5.1513 mL | 12.8783 mL | |
| 10 mM | 0.2576 mL | 1.2878 mL | 2.5757 mL | 6.4392 mL | |
| 15 mM | 0.1717 mL | 0.8586 mL | 1.7171 mL | 4.2928 mL | |
| 20 mM | 0.1288 mL | 0.6439 mL | 1.2878 mL | 3.2196 mL | |
| 25 mM | 0.1030 mL | 0.5151 mL | 1.0303 mL | 2.5757 mL | |
| 30 mM | 0.0859 mL | 0.4293 mL | 0.8586 mL | 2.1464 mL | |
| 40 mM | 0.0644 mL | 0.3220 mL | 0.6439 mL | 1.6098 mL | |
| 50 mM | 0.0515 mL | 0.2576 mL | 0.5151 mL | 1.2878 mL | |
| 60 mM | 0.0429 mL | 0.2146 mL | 0.4293 mL | 1.0732 mL | |
| 80 mM | 0.0322 mL | 0.1610 mL | 0.3220 mL | 0.8049 mL | |
| 100 mM | 0.0258 mL | 0.1288 mL | 0.2576 mL | 0.6439 mL |
CCMI Related Classifications
HY-12150 Related Classifications
Powered by Bioz